Business Standard

Itolizumab to be a blockbuster opportunity for Biocon: Kiran Mazumdar-Shaw

We felt that this was the drug that would actually have a role to play in dealing with the cytokine storm that is being seen in Covid-19 patients, says Shaw

Kiran Mazumdar-Shaw
Premium

We always expect R&D to be about 10-11% of net revenues of Biocon, excluding Syngene, says Kiran Mazumdar-Shaw

Samreen Ahmad New Delhi
Biopharmaceutical company Biocon, which saw a decline in its profit in the Q1FY21 despite a double digit growth in topline, is betting big on two recent developments. The first one is the company’s voluntary licencing agreement with Gilead to manufacture Remdesivir, the anti-viral drug which is said to be suitable for treating mild to moderate Covid-19 patients. The second one is the company’s novel biologic drug Itolizumab, which has received emergency approval to treat Covid-19 patients in India. In an interview, Biocon’s Executive Chairperson Kiran Mazumdar-Shaw tells Samreen Ahmad that the demand for both the drugs is going to be

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 24 2020 | 8:19 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com